Abrilada 40 mg / 0.8 ml Injektionslösung Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

abrilada 40 mg / 0.8 ml injektionslösung

pfizer ag - adalimumabum - injektionslösung - adalimumabum 40 mg, histidinum, histidini hydrochloridum monohydricum, dinatrii edetas corresp. natrium 5 µg, saccharum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad suspensionem pro 0.8 ml. - polyartikuläre juvenile arthritis, morbus crohn bei kindern und jugendlichen - biotechnologika

Yuflyma 40 mg solution injectable en seringue préremplie Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

yuflyma 40 mg solution injectable en seringue préremplie

iqone healthcare switzerland sa - adalimumabum - solution injectable en seringue préremplie - adalimumabum 40 mg, acidum aceticum, natrii acetas trihydricus corresp. natrium 0.07 mg, glycinum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 0.4 ml. - polyarthrite rhumatoïde, arthrite juvénile idiopathique polyarticulaire, arthrite psoriasique, spondylarthrite ankylosante, maladie de crohn chez l'adulte, colite ulcéreuse, psoriasis chez l'adulte, l'adolescent et l'enfant, hidradénite suppurée, uvéite - biotechnologika

Tremfya Եվրոպական Միություն - գերմաներեն - EMA (European Medicines Agency)

tremfya

janssen-cilag international nv - guselkumab - psoriasis - immunsuppressiva - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Idefirix Եվրոպական Միություն - գերմաներեն - EMA (European Medicines Agency)

idefirix

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunsuppressiva - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Bimzelx Եվրոպական Միություն - գերմաներեն - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a.   - bimekizumab - psoriasis - immunsuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Zytrim 50mg Filmtablette Գերմանիա - գերմաներեն - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

zytrim 50mg filmtablette

recordati pharma gmbh - azathioprin - filmtablette - azathioprin 50.mg

Zytrim 50mg Filmtablette Գերմանիա - գերմաներեն - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

zytrim 50mg filmtablette

recordati pharma gmbh - azathioprin - filmtablette - azathioprin 50.mg

Kevzara 150 mg/1.14 ml lösung zur injektion in fertigspritze Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

kevzara 150 mg/1.14 ml lösung zur injektion in fertigspritze

sanofi-aventis (suisse) sa - sarilumabum - lösung zur injektion in fertigspritze - sarilumabum 150 mg, histidinum aut histidini hydrochloridum monohydricum, arginini hydrochloridum, saccharum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1.14 ml. - rheumatoide arthritis - biotechnologika

Kevzara 200 mg/1.14 ml lösung zur injektion in fertigspritze Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

kevzara 200 mg/1.14 ml lösung zur injektion in fertigspritze

sanofi-aventis (suisse) sa - sarilumabum - lösung zur injektion in fertigspritze - sarilumabum 200 mg, histidinum aut histidini hydrochloridum monohydricum, arginini hydrochloridum, saccharum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1.14 ml. - rheumatoide arthritis - biotechnologika

Kevzara 150 mg/1.14 ml lösung zur injektion in einen stift ausgefüllt Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

kevzara 150 mg/1.14 ml lösung zur injektion in einen stift ausgefüllt

sanofi-aventis (suisse) sa - sarilumabum - lösung zur injektion in einen stift ausgefüllt - sarilumabum 150 mg, histidinum aut histidini hydrochloridum monohydricum, arginini hydrochloridum, saccharum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1.14 ml. - rheumatoide arthritis - biotechnologika